Loading match intelligence
This market resolves to Yes if the US Food and Drug Administration approves the New Drug Application for 'Olezarsen' for familial chylomicronemia syndrome on or before July 23, 2026. Otherwise, it resolves to No. Approval must be confirmed by an FDA press release or the Drugs@FDA database.
Resolves Yes if This market resolves to Yes if the US Food and Drug Administration approves the New Drug Application for 'Olezarsen' for familial chylomicronemia syndrome on or before July 23, 2026. Otherwise, it resolves to No. Approval must be confirmed by an FDA press release or the Drugs@FDA database.
Outcome verified from fda.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
Analyzing this market…
